Why Dosage Form Affects Packaging Strategy

The physicochemical properties of the dosage form determine its susceptibility to degradation. Solid tablets may be vulnerable to moisture and oxidation, while liquid formulations require protection from microbial contamination, evaporation, and chemical instability. Hence, packaging material and design must align with the dosage form’s specific vulnerabilities.

Common Packaging Types for Oral Dosage Forms

Key Differences in Packaging Criteria

• Barrier Properties: Solid dosage forms need low WVTR (Water Vapor Transmission Rate); liquids require low extractables and leachables
• Seal Integrity: Critical for liquids to prevent leakage and microbial ingress
• Material Compatibility: Some liquids may react with plastics, while solids are generally inert
• Dosage Delivery: Liquids often require dosing spoons/syringes, impacting closure design

Stability Testing Focus: Solid vs. Liquid Forms

In long-term and accelerated stability studies:

• Solids: Assessed for hardness, friability, impurity growth, disintegration time
• Liquids: Evaluated for pH, microbial limits, viscosity, precipitation, color change

Packaging must prevent these changes by maintaining physical and chemical protection across ICH stability zones.

Regulatory Requirements for Packaging Selection

According to EMA and ICH Q1A(R2), packaging used in stability studies must reflect the final market configuration. This ensures that results are representative of real-world conditions. Packaging details must be captured in CTD Module 3.2.P.7:

• ✓ Container material and type
• ✓ Closure components and liners
• ✓ Description of protective features (e.g., UV barrier, desiccant use)
• ✓ Container closure integrity results

Physical Testing of Packaging During Stability

• Torque Testing (for screw caps on liquids)
• Seal Integrity Testing (for blister packs or vials)
• Moisture Uptake Evaluation (for solids in high humidity)
• Leachables and Extractables (for plastic bottles with syrups)
• Label Durability and Print Adhesion

Case Study: Packaging Selection for a Moisture-Sensitive Tablet vs. Syrup

A moisture-sensitive antihypertensive tablet was packaged in Alu-Alu blister with desiccant carton, while its pediatric syrup version was stored in amber PET bottle with child-resistant cap. The tablet remained stable across 40°C/75% RH zones for 6 months. However, the syrup exhibited color change due to poor UV barrier. Switching to amber glass prevented degradation. Lesson: Each dosage form demands custom packaging strategy validated through stability data.

Checklist: Dosage Form-Specific Packaging Evaluation

• ☑ Have the moisture and light sensitivity of the API been evaluated?
• ☑ Is the container material compatible with the dosage form?
• ☑ Are extractables and leachables under control for liquids?
• ☑ Is seal integrity verified for blister/vial/pouch?
• ☑ Are delivery devices (e.g., droppers, syringes) included in stability?
• ☑ Does the packaging match the final marketed presentation?

Stability Protocol Adaptations Based on Packaging

The stability protocol should specify storage orientations (upright for liquids), light protection measures, and specific test intervals for packaging integrity checks. For solids, blister packs require ongoing visual inspection for delamination, while liquids may need pH and viscosity tests at each pull point.

Best Practices in Packaging Documentation

To maintain GMP compliance and audit readiness:

• Include detailed packaging specifications in the stability protocol
• Ensure traceability of packaging material lots used in stability
• Archive container-closure validation reports
• Document change control for packaging-related updates

Refer to resources at GMP guidelines for documentation templates and packaging validation SOPs.

Conclusion

Solid and liquid oral dosage forms present distinct packaging challenges. Stability testing must account for these differences to select the right packaging configuration. Through rigorous evaluation of compatibility, permeability, and container closure integrity, pharmaceutical manufacturers can ensure product stability, regulatory compliance, and patient safety throughout the product’s shelf life.

References:

• ICH Q1A(R2) Stability Testing of New Drug Substances and Products
• USP Containers – Performance Testing
• FDA Guidance for Industry: Container Closure Systems
• EMA Guideline on Plastic Immediate Packaging Materials
• WHO Guidelines for Stability Testing of Pharmaceutical Products

This tutorial explores how packaging changes are assessed during the shelf life extension process and outlines best practices to avoid regulatory delays or rejections.

Types of Packaging Changes That Influence Shelf Life

Not all packaging changes are created equal. Agencies classify them based on their potential impact on product quality and stability. Key packaging changes include:

• Change in Primary Packaging Material: e.g., switching from PVC to PVDC blister
• Container Closure System (CCS) Modification: e.g., replacing rubber stoppers or caps
• Introduction of New Bottle/Blister Shapes: affecting surface area exposure
• Change in Barrier Properties: e.g., moving to higher moisture protection
• Switch in Secondary Packaging: e.g., new cartons or foil wraps

Each change must be supported by appropriate data and justification before shelf life can be revised or extended. For information on how to generate packaging validation data, refer to pharmaceutical packaging validation.

Role of Stability Studies in Supporting Packaging Changes

When packaging changes are introduced, new stability studies must often be conducted to evaluate the impact on the product’s shelf life. Considerations include:

• Comparative stability under ICH conditions (25°C/60% RH and 40°C/75% RH)
• Photostability tests (per ICH Q1B) if light protection differs
• Moisture permeability assessments (WVTR tests)
• Extractables and leachables (E&L) for new plastic or rubber materials

Results should demonstrate that the new packaging does not adversely affect product quality, efficacy, or safety throughout the intended shelf life.

Dossier Requirements for Shelf Life Extension with Packaging Change

Regulatory submissions involving packaging changes must be detailed and include:

• Module 3.2.P.2: Pharmaceutical development rationale for packaging
• Module 3.2.P.7: Container closure system description and specifications
• Module 3.2.P.8.1: Updated stability data supporting new packaging
• Module 1: Administrative information including a cover letter summarizing changes

For smooth approval, align the submission with current regulatory filing expectations.

Examples of Packaging Changes and Regulatory Classifications

Different agencies categorize packaging changes under different variation types:

• EMA: Type IB for minor changes, Type II for major ones like CCS change
• FDA: Prior Approval Supplement (PAS) for new materials, CBE-30 for less critical changes
• CDSCO (India): Requires post-approval change (PAC) submission with local data
• ANVISA: Type I/II classification based on impact on stability

Understanding the right submission type prevents regulatory rejection or request for additional data.

Risk-Based Approach to Packaging Variation

A risk-based approach considers the packaging change’s impact on critical quality attributes (CQAs). For example:

• Low Risk: Carton text or label design change — usually doesn’t require stability
• Medium Risk: Change in foil thickness or type — may require bridging data
• High Risk: Introduction of entirely new CCS or polymer material — mandates full stability set

Use a decision tree or Failure Mode and Effects Analysis (FMEA) during change control planning to determine submission strategy.

Case Study: Blister Pack Material Change and Shelf Life Approval

A pharmaceutical company proposed a switch from PVC blisters to PVDC blisters to improve moisture barrier properties and extend shelf life from 24 to 36 months. The regulatory team took the following steps:

1. Conducted 12-month accelerated and 6-month long-term stability with the new PVDC packs
2. Performed WVTR testing comparing both blister types
3. Documented all results in a comparative tabular format
4. Submitted a Type II variation to EMA
5. Approval was granted in 60 days without further queries

Such proactive data generation and clear documentation streamlined the approval process.

Importance of Bridging Studies

If the new packaging is expected to provide similar or better protection, a bridging study using the same formulation can be considered. This involves:

• Testing both old and new packaging in parallel
• Using statistical tools to show comparability
• Reduces need for full stability study

Bridging studies must be statistically justified and accepted by agencies such as EMA or FDA depending on the region.

Internal Coordination and Change Control

Effective internal coordination is essential before initiating any packaging changes. Ensure:

• Quality Assurance has approved the updated packaging specs
• Regulatory Affairs prepares the correct variation strategy
• Production and labeling departments are trained
• Change Control records are complete

Reference internal SOPs from pharma SOP repositories for compliant documentation and training materials.

Labeling and Artwork Considerations

In addition to the physical packaging, ensure the following are updated:

• ✅ Expiry date printed on the new packaging matches approved shelf life
• ✅ Labeling reflects any changes in storage conditions (e.g., “Protect from light”)
• ✅ Artwork control numbers and versions are updated in the documentation

Any discrepancy between packaging and labeling can lead to product recalls or inspection observations.

Conclusion

Packaging changes are a common part of product lifecycle management but must be approached strategically, especially when tied to shelf life extension. Regulatory agencies place significant weight on packaging’s role in stability, and insufficient data can delay or prevent approval. A proactive, data-driven, and cross-functional approach is essential to ensure successful regulatory outcomes and long-term product quality.

References:

• EMA Variations Guidelines
• Packaging Validation Tools
• Regulatory Filing Portal
• GMP Expectations on Packaging
• SOPs for Packaging Control